Antiviral drugs are medications used to treat viral infections by inhibiting the replication of viruses within host cells. These drugs target specific viruses or types of viruses and work by either preventing the virus from entering the host cell or by blocking key enzymes or proteins required for viral replication. Unlike antibiotics, which are used to treat bacterial infections, antiviral drugs are generally less effective, as viruses have a much simpler structure and rely on host cells to replicate. However, they can still be useful in treating some viral infections, such as influenza, herpes, and HIV.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-antiviral-drugs-market
Viral infections have steadily increased around the world during the past few decades. A virus that enters the body, exploits its cells for replication and spreads causes a viral infection. Viral infections can result in various symptoms, from minor to major, and in some instances, even life-threatening ones. Globalization is one of the main causes of the increase in viral infections. People travel and communicate with each other across boundaries, making the world more connected than ever. Viral transmission from one area to another has accelerated due to this enhanced connectedness.
Viruses have a higher chance of rapidly spreading among the populace as more and more individuals choose to reside in metropolitan regions. High air pollution is frequently found in urban settings, impairing immunity and increasing vulnerability to viral infections. Viral infections are on the rise, which is also a result of climate change. The danger of illnesses like dengue, Zika, and Lyme disease rises as temperatures rise because some mosquitoes, ticks, and other disease-carrying insects have a wider range. Natural disasters brought on by climate change may potentially be more frequent and severe, which raises the risk of viral infections by disrupting infrastructure, sanitary practices, and population movement.
Data Bridge Market Research analyses that the Antiviral Drugs Market is expected to grow with a CAGR of 5.5% in the forecast period from 2023 to 2030, and is expected to reach USD 107,700.57 million by 2030. In 2023, the Indication segment is expected to dominate the market due to the increasing prevalence of viral infections in the regions.
Key Findings of the Study
Growing Demand for Combination Therapies
Combination therapy is the application of two or more medications to manage a disease or other health issue. Combination therapy has gained popularity as a method of antiviral treatment for viral infections since it can target many stages of the virus' lifecycle and lowers the risk of drug resistance.
Combination therapy for antiviral treatment has the benefit of being able to target various viral lifecycle stages, including viral entry, replication, and release. This strategy can enhance treatment results by lowering the viral load and the risk of drug resistance.
Drug-resistant viral strains have increased the need for combination therapy to treat viruses. When a virus changes, it can no longer be treated with an antiviral drug, known as drug resistance. Combining therapy can lower the risk of medication resistance by focusing on various stages of the viral lifecycle, making it more challenging for the virus to build resistance.
A growing global population, aging populations, the incidence of chronic diseases, and technological improvements are only a few factors contributing to the increase in demand for sophisticated pharmaceutical and biotechnology products. Due to this, there is a greater requirement for antiviral drugs and increasing demand for pharmaceuticals and treatments.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, France, U.K, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Gilead Sciences, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K.), Abbvie, Merck & Co., Inc. (U.S), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb Company (New York), Cipla Inc. (India), Aurobindo Pharma (U.S), Dr. Reddy’s Laboratories Ltd. (India), Zydus Pharmaceuticals, Inc. (U.S.), Mylan Pharmaceuticals ULC (U.S), Teva Pharmaceuticals USA Inc. (Israel), EMERGENT (U.S.), Sun Pharmaceutical Industries Ltd. (India), Avet Pharmaceuticals Inc. (U.S.), Pfizer Inc. (U.S.), SIGA Technologies (U.S.), NAVINTA LLC. (U.S.), Macleods Pharmaceuticals Ltd. (India), BioCryst Pharmaceuticals, Inc, (U.S.), and Hetero. (India) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global antiviral drugs market is categorized into six notable segments based on indication, patient type, products, drug type, end user, and distribution channel.
- On the basis of indication, the global antiviral drugs market is segmented into influenza, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus, herpes simplex virus, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), hepatitis B virus (HBV), coronavirus infection, and others.
In 2023, the influenza segment is expected to dominate the global antiviral drugs market with a 33.99% market share
In 2023, the influenza segment by indication will dominate the antiviral drug market as the prevalence of influenza continues to be a significant public health issue, the demand for effective antiviral drugs to treat and prevent the infection is expected to remain high. This is expected to drive the growth of the global antiviral drug market. Pharmaceutical companies continue to invest in the development of new antiviral therapies and combination therapies to improve the effectiveness of treatment for influenza.
- On the basis of patient type, the global antiviral drugs market is segmented into child, adult, and geriatric. In 2023, the geriatric segment is expected to dominate the global antiviral drugs market with a 48.66% market share.
- On the basis of products, the global antiviral drugs market is segmented into oral, topical, and parenteral. In 2023, the oral segment is expected to dominate the global antiviral drugs market with a 64.13% market share.
- On the basis of drug type, the global antiviral drugs market is segmented into generic and branded. In 2023, the generic segment is expected to dominate the global antiviral drugs market with a 65.44% market share.
In 2023, the generic segment in drug type is expected to dominate the global antiviral drugs market
- On the basis of end user, the global antiviral drugs market is segmented into hospitals, clinics, home healthcare, specialty centers, ambulatory centers, and others. In 2023, the hospitals segment is expected to dominate the global antiviral drugs market with a 51.52% market share.
- On the basis of distribution channel, the global antiviral drugs market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. In 2023, the hospital pharmacy segment is expected to dominate the global antiviral drugs market with a 53.65% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the global antiviral drugs market are Gilead Sciences, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K.), Abbvie, Merck & Co., Inc. (U.S), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb Company (New York), Cipla Inc. (India), Aurobindo Pharma (U.S), Dr. Reddy’s Laboratories Ltd.(India), Zydus Pharmaceuticals, Inc. (U.S.), Mylan Pharmaceuticals ULC (U.S), Teva Pharmaceuticals USA Inc. (Israel), EMERGENT (U.S.), Sun Pharmaceutical Industries Ltd.(India), Avet Pharmaceuticals Inc. (U.S.), Pfizer Inc. (U.S.), SIGA Technologies (U.S.), NAVINTA LLC. (U.S.), Macleods Pharmaceuticals Ltd. (India), BioCryst Pharmaceuticals, Inc, (U.S.), and Hetero. (India) among others.
Market Development
- In November 2022, SIGA Technologies announced that they set out to make a smallpox therapy in case the eradicated virus was ever used as a bioweapon. U.S. regulators approved the resulting oral antiviral, TPOXX (tecovirimat), largely based on the animal study. This will help the company in product expansion.
- In January 2022, Aurobindo Pharma announced that Molnupiravir under the brand Molnaflu is available widely across the country. Molnupiravir is for the treatment of adult patients with COVID-19 who have a high risk of disease, including hospitalization.
- In December 2021, Roche announced that it completed the repurchase of Roche shares that had been held by Novartis. Roche and Novartis had announced this repurchase. The repurchase will help in the growth of the revenue of Roche.
- In December 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted conditional marketing authorization for Xevudy (sotrovimab) for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection. The product grant will help in further growth of the revenue.
- In October 2020, Johnson & Johnson announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovers and develops novel therapies for immune-mediated diseases, in an all-cash transaction for approximately USD 6.5 billion. This acquisition will help in revenue growth.
Regional Analysis
Geographically, the countries covered in the Antiviral Drugs market report are U.S., Canada, and Mexico, Germany, France, U.K, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, and Rest of Middle East and Africa as per Data Bridge Market Research analysis.
North America is the dominant region in the antiviral drugs market during the forecast period 2023 - 2030
In 2023, North America dominated the antiviral drugs market owing to the higher level of investments by various manufacturers and increasing advancements in drug development in the region. North America will continue to dominate the antiviral drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.
Asia-Pacific is the fastest growing region in the antiviral drugs market during the forecast period 2023 - 2030
Asia-Pacific is estimated to be the fastest growing region in the antiviral drugs market for the forecast period 2023 -2030. This is due to the growing demand for combination therapies in the region and the rise in the prevalence of antiviral drugs.
For more detailed information about the antiviral drugs report, click here – https://www.databridgemarketresearch.com/reports/global-antiviral-drugs-market
